Rabeprazole: Quest for the best PPI

Journal of Gastroenterology

Volumn 37, Issue 3, 2002, Pages 233-234

  Sugano, Kentaro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; BIOCHEMISTRY; CELL STRUCTURE; CLINICAL STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; EDITORIAL; ENTEROCHROMAFFIN CELL; GASTROESOPHAGEAL REFLUX; HUMAN; INHIBITION KINETICS; JAPAN; LICENSING; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RAT; REFLUX ESOPHAGITIS; STOMACH ACID; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; ENTEROCHROMAFFIN CELLS; GASTRINS; HUMANS; OMEPRAZOLE; PARIETAL CELLS, GASTRIC; RATS;

EID: 0036219305     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350200028     Document Type: Editorial

References (16)

1. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
2. The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: A comparison with omeprazole
3. The potency of substituted benzimidazoles such as E3810, omperazole, Ro 18-5364 to inhibit gastric H+, K+-ATPase is correlated with the rate of acid activation of the inhibitor
4. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione
5. Sites of action of the gastric H, K-ATPase with extracytoplasmic thiol reagents
6. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastric concentrations in young healthy male subjects
7. Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study
8. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active duodenal ulcer-a European multicentre study
9. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. A double-blind, multicenter, European trial
10. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease
11. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
12. Decreasing oesophageal acid exposure in patients with GERD: A comparison of rabeprazole and omeprazole
13. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole
14. Proton pump inhibitors and their drug interactions: An evidence-based approach
15. New-generation proton pump inhibitors: Overcoming the limitations of early-generation agents
16. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial